Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1984 Nov;18(5):765–771. doi: 10.1111/j.1365-2125.1984.tb02540.x

Ketanserin in combination with beta-adrenergic receptor blocking agents in the treatment of essential hypertension.

T Hedner, B Persson
PMCID: PMC1463538  PMID: 6150724

Abstract

The antihypertensive properties of ketanserin, a 5-HT2 receptor antagonist, was investigated in combination with beta-adrenoceptor blockade. Ketanserin was given 40 mg twice daily to 10 hypertensive patients during 4 weeks in a double-blind placebo-controlled trial. Ketanserin significantly reduced supine and erect blood pressure compared to double-blind placebo, while no changes in heart rate were seen. When the blood pressure was assessed during 24 h at steady state conditions, the blood pressure reduction was maximal 1-2 h after tablet intake, corresponding to peak plasma concentrations of ketanserin. The blood pressure remained significantly reduced until next tablet intake (12 h). At steady state, on a 40 mg twice daily regimen, Css was 41.6 +/- 4.22, 36.9 +/- 5.19 and 39.8 +/- 4.81 ng/ml, Cmax 102.4 +/- 15.64 ng/ml and tmax 1.6 +/- 0.32 h. A slight sedation was observed in six patients. This side effect occurred 1-2 h after tablet intake and tended to subside with continued treatment.

Full text

PDF
768

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrén L., Svensson A., Dahlöf B., Eggertsen R., Hansson L. Ketanserin in hypertension. Early clinical evaluation and dose finding study of a new 5-HT2 receptor antagonist. Acta Med Scand. 1983;214(2):125–130. [PubMed] [Google Scholar]
  2. De Cree J., Leempoels J., De Cock W., Geukens H., Verhaegen H. The antihypertensive effects of a pure and selective serotonin-receptor blocking agent (R 41 468) in elderly patients. Angiology. 1981 Feb;32(2):137–144. doi: 10.1177/000331978103200206. [DOI] [PubMed] [Google Scholar]
  3. Demoulin J. C., Bertholet M., Soumagne D., David J. L., Kulbertus H. E. 5-HT2-receptor blockade in the treatment of heart failure. A preliminary study. Lancet. 1981 May 30;1(8231):1186–1188. doi: 10.1016/s0140-6736(81)92352-7. [DOI] [PubMed] [Google Scholar]
  4. Fozard J. R. Mechanism of the hypotensive effect of ketanserin. J Cardiovasc Pharmacol. 1982 Sep-Oct;4(5):829–838. doi: 10.1097/00005344-198209000-00020. [DOI] [PubMed] [Google Scholar]
  5. Hedner T., Persson B., Berglund G. Experience with ketanserin, a serotonin (S2) antagonist, in longterm treatment of essential hypertension. Clin Exp Hypertens A. 1984;6(3):743–751. doi: 10.3109/10641968409044035. [DOI] [PubMed] [Google Scholar]
  6. Hedner T., Persson B., Berglund G. Ketanserin, a novel 5-hydroxytryptamine antagonist: monotherapy in essential hypertension. Br J Clin Pharmacol. 1983 Aug;16(2):121–125. doi: 10.1111/j.1365-2125.1983.tb04974.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kalkman H. O., Timmermans P. B., Van Zwieten P. A. Characterization of the antihypertensive properties of ketanserin (R 41 468) in rats. J Pharmacol Exp Ther. 1982 Jul;222(1):227–231. [PubMed] [Google Scholar]
  8. Leysen J. E., Awouters F., Kennis L., Laduron P. M., Vandenberk J., Janssen P. A. Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors. Life Sci. 1981 Mar 2;28(9):1015–1022. doi: 10.1016/0024-3205(81)90747-5. [DOI] [PubMed] [Google Scholar]
  9. Nyberg G. Indirect blood pressure and heart rate measured quickly without observer bias using a semi-automatic machine (auto-manometer)--response to isometric exercise in normal healthy males and its modification by beta-adrenoceptor blockade. Br J Clin Pharmacol. 1977 Jun;4(3):275–281. doi: 10.1111/j.1365-2125.1977.tb00712.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Okonkwo P. O., Reimann I. W., Woestenborghs R., Klotz U. High-performance liquid chromatographic assay with fluorometric detection of ketanserin, a new antihypertensive agent and serotonin S2 antagonist in human plasma, blood and urine. J Chromatogr. 1983 Feb 11;272(2):411–416. doi: 10.1016/s0378-4347(00)86149-6. [DOI] [PubMed] [Google Scholar]
  11. Persson B., Hedner T., Berglund G. Ketanserin in essential hypertension: effects during rest and exercise. Eur J Clin Pharmacol. 1983;25(3):307–312. doi: 10.1007/BF01037939. [DOI] [PubMed] [Google Scholar]
  12. Persson B., Hedner T., Henning M. Cardiovascular effects in the rat of ketanserin, a novel 5-hydroxytryptamine receptor blocking agent. J Pharm Pharmacol. 1982 Jul;34(7):442–445. doi: 10.1111/j.2042-7158.1982.tb04753.x. [DOI] [PubMed] [Google Scholar]
  13. Reimann I. W., Frölich J. C. Mechanism of antihypertensive action of ketanserin in man. Br Med J (Clin Res Ed) 1983 Aug 6;287(6389):381–383. doi: 10.1136/bmj.287.6389.381-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Samuelsson O., Andersson O., Wilhelmsen L., Berglund G. Treatment of hypertension at an outpatient hypertension clinic. Blood pressure control, dropout rate, and side effects. Prev Med. 1982 Sep;11(5):521–535. doi: 10.1016/0091-7435(82)90066-4. [DOI] [PubMed] [Google Scholar]
  15. Van Nueten J. M., Janssen P. A., Van Beek J., Xhonneux R., Verbeuren T. J., Vanhoutte P. M. Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors. J Pharmacol Exp Ther. 1981 Jul;218(1):217–230. [PubMed] [Google Scholar]
  16. Wenting G. J., Man in 't Veld A. J., Woittiez A. J., Boomsma F., Schalekamp M. A. Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist. Br Med J (Clin Res Ed) 1982 Feb 20;284(6315):537–539. doi: 10.1136/bmj.284.6315.537. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Wenting G. J., Woittiez A. J., Man in't Veld A. J., Schalekamp M. A. 5-HT, alpha-adrenoceptors, and blood pressure. Effects of ketanserin in essential hypertension and autonomic insufficiency. Hypertension. 1984 Jan-Feb;6(1):100–109. doi: 10.1161/01.hyp.6.1.100. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES